Showing results (391-400 of 3,470) with videos related to
Sort By:
Pageof 347
Clinical Pharmacokinetics|February 8, 2011
Pharmacokinetic optimization of antiretroviral therapy in children and adolescentsMichael N Neely, Natella Y RakhmaninaClinical Pharmacokinetics|July 12, 2011
Prediction of human oral plasma concentration-time profiles using preclinical data: comparative evaluation of prediction approaches in early pharmaceutical discoveryAn Van den Bergh, Vikash Sinha, Ron Gilissen, et al.Clinical Pharmacokinetics|March 23, 2007
Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsisFlorian M E Wagenlehner, Wolfgang Weidner, Kurt G NaberClinical Pharmacokinetics|August 24, 2007
Integrated pharmacokinetics and pharmacodynamics in drug developmentJasper Dingemanse, Silke Appel-DingemanseClinical Pharmacokinetics|August 24, 2007
Phase I evaluation of the safety, pharmacokinetics and pharmacodynamics of CP-481,715Alan T Clucas, Ajit Shah, Yuanchao Derek Zhang, et al.Clinical Pharmacokinetics|December 14, 2011
A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapyCéline Verstuyft, Xavier Delavenne, Alexandra Rousseau, et al.Clinical Pharmacokinetics|November 18, 2011
Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?Christine E Staatz, Susan E TettClinical Pharmacokinetics|November 18, 2011
Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphomaAndrzej Hellmann, Simon Rule, Jan Walewski, et al.Clinical Pharmacokinetics|February 10, 2012
Allometric or lean body mass scaling of propofol pharmacokinetics: towards simplifying parameter sets for target-controlled infusionsJohan Francois CoetzeePageof 347